611 related articles for article (PubMed ID: 28271908)
1. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.
Nagaraj K; Narendar D; Kishan V
Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908
[TBL] [Abstract][Full Text] [Related]
2. Development of olmesartan medoxomil lipid-based nanoparticles and nanosuspension: preparation, characterization and comparative pharmacokinetic evaluation.
B A; D N; Veerabrahma K
Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):126-137. PubMed ID: 28290712
[TBL] [Abstract][Full Text] [Related]
3. Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study.
Gora S; Mustafa G; Sahni JK; Ali J; Baboota S
Drug Deliv; 2016; 23(3):940-50. PubMed ID: 24937379
[TBL] [Abstract][Full Text] [Related]
4. Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers.
Alsofany JM; Hamza MY; Abdelbary AA
AAPS PharmSciTech; 2018 Jul; 19(5):2118-2132. PubMed ID: 29700766
[TBL] [Abstract][Full Text] [Related]
5. Formulation of lyophilized oily-core poly-Ɛ-caprolactone nanocapsules to improve oral bioavailability of Olmesartan Medoxomil.
Khattab WM; Zein El-Dein EE; El-Gizawy SA
Drug Dev Ind Pharm; 2020 May; 46(5):795-805. PubMed ID: 32275456
[No Abstract] [Full Text] [Related]
6. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
7. Formulation, optimization, and in vitro-in vivo evaluation of olmesartan medoxomil nanocrystals.
Jain S; Patel K; Arora S; Reddy VA; Dora CP
Drug Deliv Transl Res; 2017 Apr; 7(2):292-303. PubMed ID: 28116656
[TBL] [Abstract][Full Text] [Related]
8. Lipid nanoparticles of zaleplon for improved oral delivery by Box-Behnken design: optimization, in vitro and in vivo evaluation.
Dudhipala N; Janga KY
Drug Dev Ind Pharm; 2017 Jul; 43(7):1205-1214. PubMed ID: 28274147
[TBL] [Abstract][Full Text] [Related]
9. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation.
Nooli M; Chella N; Kulhari H; Shastri NR; Sistla R
Drug Dev Ind Pharm; 2017 Apr; 43(4):611-617. PubMed ID: 28005442
[TBL] [Abstract][Full Text] [Related]
10. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation.
Patel GV; Patel VB; Pathak A; Rajput SJ
Drug Dev Ind Pharm; 2014 Jan; 40(1):80-91. PubMed ID: 23323843
[TBL] [Abstract][Full Text] [Related]
11. Design and development of a self-microemulsifying drug delivery system of olmesartan medoxomil for enhanced bioavailability.
Komesli Y; Burak Ozkaya A; Ugur Ergur B; Kirilmaz L; Karasulu E
Drug Dev Ind Pharm; 2019 Aug; 45(8):1292-1305. PubMed ID: 30986085
[TBL] [Abstract][Full Text] [Related]
12. Solid lipid nanoparticles as an efficient drug delivery system of olmesartan medoxomil for the treatment of hypertension.
Pandya NT; Jani P; Vanza J; Tandel H
Colloids Surf B Biointerfaces; 2018 May; 165():37-44. PubMed ID: 29453084
[TBL] [Abstract][Full Text] [Related]
13. Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment.
Kamran M; Ahad A; Aqil M; Imam SS; Sultana Y; Ali A
Int J Pharm; 2016 May; 505(1-2):147-58. PubMed ID: 27005906
[TBL] [Abstract][Full Text] [Related]
14. Nanosuspensions as delivery system for gambogenic acid: characterization and in vitro/in vivo evaluation.
Yuan H; Li X; Zhang C; Pan W; Liang Y; Chen Y; Chen W; Liu L; Wang X
Drug Deliv; 2016 Oct; 23(8):2772-2779. PubMed ID: 26292058
[TBL] [Abstract][Full Text] [Related]
15. Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability.
Kaithwas V; Dora CP; Kushwah V; Jain S
Colloids Surf B Biointerfaces; 2017 Jun; 154():10-20. PubMed ID: 28284054
[TBL] [Abstract][Full Text] [Related]
16. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
Gajera BY; Shah DA; Dave RH
Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
[TBL] [Abstract][Full Text] [Related]
17. Rutin nanosuspension for potential management of osteoporosis: effect of particle size reduction on oral bioavailability,
Gera S; Pooladanda V; Godugu C; Swamy Challa V; Wankar J; Dodoala S; Sampathi S
Pharm Dev Technol; 2020 Oct; 25(8):971-988. PubMed ID: 32403972
[TBL] [Abstract][Full Text] [Related]
18. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes.
Patel PJ; Gajera BY; Dave RH
Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778
[TBL] [Abstract][Full Text] [Related]
19. Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension.
Guo JJ; Yue PF; Lv JL; Han J; Fu SS; Jin SX; Jin SY; Yuan HL
Int J Pharm; 2013 Jan; 441(1-2):227-33. PubMed ID: 23220096
[TBL] [Abstract][Full Text] [Related]
20. Development of zolmitriptan transfersomes by Box-Behnken design for nasal delivery: in vitro and in vivo evaluation.
Pitta SK; Dudhipala N; Narala A; Veerabrahma K
Drug Dev Ind Pharm; 2018 Mar; 44(3):484-492. PubMed ID: 29124986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
